Search research articles
Contact Us
Filters
Showing results (321-330 of 488) with videos related to
Page
of 49
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
February 16, 2019
Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment
Stefan Diem, Mirjam Fässler, David Bomze, et al.
European Journal of Immunology
|
July 13, 2002
T cell receptor transgenic mice recognizing the immunodominant epitope of the Torpedo californica acetylcholine receptor
Adrian A Lobito, Bingzhi Yang, Marcela F Lopes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 7, 2012
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma
F Morschhauser, C Recher, N Milpied, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2026
Phase 1 Study of KITE-222, an Autologous CLL-1-directed CAR T-cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Naval Daver, James S Blachly, Armin Ghobadi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 27, 2011
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure
Thomas Prébet, Steven D Gore, Benjamin Esterni, et al.
Experimental Hematology & Oncology
|
September 18, 2015
The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis
Mary Frances McMullin, Claire N Harrison, Dietger Niederwieser, et al.
American Journal of Hematology
|
September 12, 2025
Association Between Molecular Profile and Outcome After Intensive Chemotherapy in Patients > 60 Years With Secondary and/or Adverse Cytogenetics Acute Myeloid Leukemia-A FILO Study
Corentin Orvain, Anne Bouvier, Audrey Bidet, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 20, 2006
Functional CD8+ but not CD4+ T cell responses develop independent of thymic epithelial MHC
Marianne M Martinic, Maries F van den Broek, Thomas Rülicke, et al.
The Journal of Experimental Medicine
|
December 7, 2011
Immature B cells preferentially switch to IgE with increased direct Sμ to Sε recombination
Duane R Wesemann, Jennifer M Magee, Cristian Boboila, et al.
Frontiers in Immunology
|
March 5, 2025
Recognition of MR1-antigen complexes by TCR Vγ9Vδ2
José Pedro Loureiro, Alessandro Vacchini, Giuliano Berloffa, et al.
Page
of 49
Search research articles
Search
Showing results (321-330 of 488) with videos related to
Sort By:
Page
of 49
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
February 16, 2019
Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment
Stefan Diem, Mirjam Fässler, David Bomze, et al.
European Journal of Immunology
|
July 13, 2002
T cell receptor transgenic mice recognizing the immunodominant epitope of the Torpedo californica acetylcholine receptor
Adrian A Lobito, Bingzhi Yang, Marcela F Lopes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 7, 2012
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma
F Morschhauser, C Recher, N Milpied, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2026
Phase 1 Study of KITE-222, an Autologous CLL-1-directed CAR T-cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Naval Daver, James S Blachly, Armin Ghobadi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 27, 2011
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure
Thomas Prébet, Steven D Gore, Benjamin Esterni, et al.
Experimental Hematology & Oncology
|
September 18, 2015
The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis
Mary Frances McMullin, Claire N Harrison, Dietger Niederwieser, et al.
American Journal of Hematology
|
September 12, 2025
Association Between Molecular Profile and Outcome After Intensive Chemotherapy in Patients > 60 Years With Secondary and/or Adverse Cytogenetics Acute Myeloid Leukemia-A FILO Study
Corentin Orvain, Anne Bouvier, Audrey Bidet, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 20, 2006
Functional CD8+ but not CD4+ T cell responses develop independent of thymic epithelial MHC
Marianne M Martinic, Maries F van den Broek, Thomas Rülicke, et al.
The Journal of Experimental Medicine
|
December 7, 2011
Immature B cells preferentially switch to IgE with increased direct Sμ to Sε recombination
Duane R Wesemann, Jennifer M Magee, Cristian Boboila, et al.
Frontiers in Immunology
|
March 5, 2025
Recognition of MR1-antigen complexes by TCR Vγ9Vδ2
José Pedro Loureiro, Alessandro Vacchini, Giuliano Berloffa, et al.
Page
of 49